So, how’s it going?
Last January, we compiled a list of “burning questions” for a group of the largest and most closely followed biotech companies. Answers to these questions — encompassing financial performance, clinical trial milestones, and regulatory approvals — can make or break a company’s performance during the year.
August is almost here, so we figured it was a good opportunity to see how many of this year’s biotech burning questions have been answered, and what lies ahead.
